News

Human Genome Sciences has submitted a Biologics License Application (BLA) to the FDA for Zalbin (albinterferon alfa-2b) for the treatment of chronic hepatitis C. The BLA submission includes

UK-based Synexus has recruited the highest number of patients to the South African study investigating a paediatric vaccine against rotavirus. The company recruited in excess of two thousand

Accovion supports CSL Behring in successfully obtaining marketing authorisation for Berinert Berinert, a human C1 esterase inhibitor (C1-INH) for treating acute episodes of facial or abdominal hereditary angioedema

Biovitrum has completed the first of two clinical phase II studies, designed to together show proof of concept of Kiobrina (rhBSSL) in preterm infants. The results show statistically

Ipsen has initiated an international, multi-center, controlled, randomised Phase II clinical trial to evaluate the safety and efficacy of BN83495, its investigational steroid sulfatase (STS) inhibitor, in advanced

Merge Healthcare has announced that InSite One has expanded its contract with Merge to provide a universal viewing solution for their InDex archiving services. Jim Champagne, president of

Novartis has gained exclusive rights to two oral targeted investigational therapies for patients with a range of life-threatening blood disorders and cancers that currently do not have effective

Unilife Medical Solutions has filed patent applications in the US for a new ready-to-fill syringe product to be marketed as the Unifill Select. The Unifill Select is a

Gen-Probe’s subsidiary, Prodesse has received FDA clearence for marketing its ProParaflu+ assay in the US. Its a molecular test that detects and differentiates parainfluenza 1, 2 and 3